EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rethinking EPO: A Paradigm Shift in Oncology?

Jean-Marc Ferrero, Baharia Mograbi iD, Rym Bouriga iD, Jocelyn Gal iD, Gérard Milano

Cancers · 03.12.2025 · 17 (23) · 3875

DOI: 10.3390/cancers17233875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.12.2025. Verfasst von Jean-Marc Ferrero und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietin (EPO) is a hormone mainly produced by the kidney. EPO stimulates red blood cell production in response to hypoxia. EPO represents one of the most compelling paradoxes in medical oncology. For decades, recombinant EPO has been prescribed as an effective therapy for cancer-related anemia and fatigue, significantly improving patients’ quality of life while reducing their dependence on blood transfusions. Yet, accumulating scientific evidence knowledge has highlighted the complex interactions between EPO and tumor biology that extend well beyond its hematopoietic functions. The putative expression of EPO receptors on tumor cells has raised concerns about a potential role of EPO in promoting tumor progression, although conclusive clinical evidence remains lacking. Recent studies have revealed that EPO may contribute to immunosuppressive mechanisms within the tumor microenvironment, thereby reshaping our understanding of its risk/benefit profile in oncology. This evolving body of evidence calls for an objective reassessment of EPO’s dual nature as both a therapeutic ally and a potential oncological threat, in order to bring more caution around decision-making in the current era of strongly evolving cancer care.

Schlagwörter

Stichwörter der Autor:innen

anemiacancer treatmenterythropoietinimmunotherapymacrophage

Autor:innen und Institutionen

  • Department of Medical Oncology, Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.
  • Institute for Research on Ageing and Cancer, Nice (IRCAN), Institut Hospitalo-Universitaire (IHU) RespirERA, Fédérations Hospitalo-Universitaires (FHU) OncoAge, Centre National de la Recherche Scientifique (CNRS) 7284,…
  • Medical Oncologist, Park Imperial Clinic, 28 Boulevard du Tzarewitch, 06000 Nice, France.
  • Department of Epidemiology and Biostatistics, Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.
  • Scientific Valorization, Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.

ORCID-Profile: Baharia Mograbi, Rym Bouriga, Jocelyn Gal

Förderung

  • French National Research Agency

Zitieren

APA

Ferrero, J. M., Mograbi, B., Bouriga, R., Gal, J., & Milano, G. (2025). Rethinking EPO: A Paradigm Shift in Oncology?. Cancers, 17(23), 3875. https://doi.org/10.3390/cancers17233875

Vancouver

Ferrero JM, Mograbi B, Bouriga R, Gal J, Milano G. Rethinking EPO: A Paradigm Shift in Oncology?. Cancers. 2025;17(23):3875. doi:10.3390/cancers17233875

BibTeX
@article{Ferrero2025,
  author = {Ferrero, Jean-Marc and Mograbi, Baharia and Bouriga, Rym and Gal, Jocelyn and Milano, Gérard},
  title = {Rethinking EPO: A Paradigm Shift in Oncology?},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {23},
  pages = {3875},
  doi = {10.3390/cancers17233875}
}
Kostenlos starten →